Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  inotuzumab ozogamicin
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-6 of 6 for your search:
Start Over
Inotuzumab Ozogamycin in Elderly Acute Lymphoblastic Leukemia (ALL)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: 2010-0991, NCI-2011-01123, NCT01371630
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2012-0265, NCI-2012-02072, NCT01664910
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome (PC) Positive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2014-0435, NCI-2014-02606, NCT02311998
Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UCL 11/0475, NCT01679119
Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IOSI-LND-001, NCT01535989
S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: S1312, NCI-2013-01368, U10CA180888, U10CA032102, NCT01925131
Start Over